US EditionFDA Approves New Generic Abortion Pill as Lawsuit Moves to Missouri
The lawsuit demands tighter restrictions on mifepristone, including limiting use to seven weeks and requiring three in-person doctor visits, amid claims of safety concerns.
- The FDA has approved a new generic version of mifepristone, manufactured by Evita Solutions, which is approved for pregnancies up to ten weeks.
- U.S. District Judge Matthew Kacsmaryk transferred the abortion drug lawsuit from Texas to Missouri, allowing the anti-abortion medical coalition to continue their fight against mifepristone.
- Health and Human Services Secretary Robert F. Kennedy Jr. has announced a review of mifepristone's safety, responding to pressure from abortion opponents.
- Opposition from anti-abortion advocates has intensified, with statements condemning the FDA's actions as a betrayal of the pro-life movement, especially from figures like Former Vice President Mike Pence.
171 Articles
171 Articles
This decision, which serves as a routine procedure, was strongly criticized by the president of the powerful anti-abortion association Students for Life Action.
The authorisation of a new generic of mifepristone in the United States revives the debate on access to abortion and provokes a strong reaction from conservative circles The American Agency for
Federal officials approved another rich version of the mifepristone abortive gland, causing rejection of conservatives.
Washington, Oct 2 (EFE).- The U.S. Food and Drug Administration (FDA) approved on Thursday a new generic version of the abortion pill mifepristone, one of two drugs used in abortion with medication up to ten weeks of pregnancy. Evita Solutions received authorization to market its product, becoming the second pharmaceutical with an approved generic of this medicine, along with GenBioPro. “When an equivalence application meets the requirements of …
U.S. regulators approved a new generic version of the mifepristone abortion pill, sparking protests from conservative sectors. Anti-abortion groups and personalities condemned the regulatory measure. Student for Life Action called it "a stain on the presidency of (Donald) Trump." The pharmacist Evita announced on her website that the Food and Drug Administration (FDA) approved this week its generic version of mifepristone, used to interrupt preg…
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
